Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1989 Dec;340(6):684-8.
doi: 10.1007/BF00717745.

Characterization of the K(+)-channel-coupled adenosine receptor in guinea pig atria

Affiliations

Characterization of the K(+)-channel-coupled adenosine receptor in guinea pig atria

H Tawfik-Schlieper et al. Naunyn Schmiedebergs Arch Pharmacol. 1989 Dec.

Abstract

In the present work we studied the pharmacological profile of adenosine receptors in guinea pig atria by investigating the effect of different adenosine analogues on 86Rb(+)-efflux from isolated left atria and on binding of the antagonist radioligand 8-cyclopentyl-1,3-[3H]dipropylxanthine [( 3H]DPCPX) to atrial membrane preparations. The rate of 86Rb(+)-efflux was increased twofold by the maximally effective concentrations of adenosine receptor agonists. The EC50-values for 2-chloro-N6-cyclopentyladenosine (CCPA), R-N6-phenylisopropyladenosine (R-PIA), 5'-N-ethylcarboxamidosadenosine (NECA), and S-N6-phenylisopropyladenosine (S-PIA) were 0.10, 0.14, 0.24 and 12.9 microM, respectively. DPCPX shifted the R-PIA concentration-response curve to the right in a concentration-dependent manner with a KB-value of 8.1 nM, indicating competitive antagonism. [3H]DPCPX showed a saturable binding to atrial membranes with a Bmax-value of 227 fmol/mg protein and a KD-value of 1.3 nM. Competition experiments showed a similar potency for the three agonists CCPA, R-PIA and NECA. S-PIA is 200 times less potent than R-PIA. Our results suggest that the K+ channel-coupled adenosine receptor in guinea pig atria is of an A1 subtype.

PubMed Disclaimer

References

    1. J Pharmacol Exp Ther. 1965 May;148:202-14 - PubMed
    1. J Neurosci. 1987 Oct;7(10):3306-16 - PubMed
    1. Circ Res. 1978 Nov;43(5):785-92 - PubMed
    1. J Pharmacol Exp Ther. 1984 Aug;230(2):483-92 - PubMed
    1. Naunyn Schmiedebergs Arch Pharmacol. 1988 Jun;337(6):687-9 - PubMed

Publication types